Analysts Set Zenas BioPharma, Inc. (NASDAQ:ZBIO) Price Target at $43.14

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $43.1429.

Several research analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Jefferies Financial Group restated a “buy” rating and set a $48.00 price target on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Wedbush reiterated an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research report on Monday, December 22nd. Citigroup lifted their price objective on Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $44.00 price target on shares of Zenas BioPharma in a research note on Tuesday.

Zenas BioPharma Stock Down 4.4%

Shares of ZBIO stock opened at $21.48 on Wednesday. Zenas BioPharma has a 12 month low of $6.11 and a 12 month high of $44.60. The company has a quick ratio of 5.66, a current ratio of 5.66 and a debt-to-equity ratio of 0.37. The firm has a market cap of $1.15 billion, a PE ratio of -3.04 and a beta of -1.50. The stock has a 50 day moving average of $28.32 and a 200-day moving average of $25.52.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Buying and Selling at Zenas BioPharma

In other Zenas BioPharma news, CEO Leon O. Moulder, Jr. bought 57,000 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were acquired at an average cost of $17.96 per share, for a total transaction of $1,023,720.00. Following the transaction, the chief executive officer owned 423,155 shares in the company, valued at approximately $7,599,863.80. The trade was a 15.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last quarter, insiders have bought 157,000 shares of company stock worth $2,662,720. 16.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Federated Hermes Inc. grew its stake in shares of Zenas BioPharma by 60.8% in the 2nd quarter. Federated Hermes Inc. now owns 1,861,838 shares of the company’s stock valued at $18,041,000 after purchasing an additional 703,838 shares during the period. Vanguard Group Inc. lifted its position in shares of Zenas BioPharma by 25.0% during the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock worth $52,761,000 after buying an additional 290,307 shares during the period. Invesco Ltd. acquired a new stake in Zenas BioPharma in the 3rd quarter valued at $3,237,000. Goldman Sachs Group Inc. acquired a new stake in Zenas BioPharma in the 4th quarter valued at $4,746,000. Finally, Geode Capital Management LLC grew its position in Zenas BioPharma by 25.2% in the fourth quarter. Geode Capital Management LLC now owns 588,393 shares of the company’s stock valued at $21,371,000 after acquiring an additional 118,358 shares during the period.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.